Compare Citius Pharmaceuticals Inc (CTXR) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Rush Street Interactive Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Rush Street Interactive Inc trades at $19.24 (market cap $2.35B). The key difference: Rush Street Interactive Inc is far larger — about 172.5× Citius Pharmaceuticals Inc's market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Rush Street Interactive Inc for 13 Days on average.
| CTXR | RSI | |
|---|---|---|
Market Cap | $13.62M | $2.35B |
Volume | 132,438 | 2,219,374 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $34.52 |
52-Week Low | $0.48 | $15.89 |
Typical Hold Time | 17 Days | 13 Days |
Enterprise Value | $3.79M | $2.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
RSI trades at $19.32, down 4.55% today, with bearish technical signals from moving averages but neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue grew to $1.13B in 2025 with a net income margin of 2.33%, though profitability faces pressure as margins are expected to compress slightly in 2026. Analyst sentiment remains strongly positive with a consensus price target of $34.88, representing significant upside potential from current levels.
The stock presents a compelling opportunity given the substantial analyst upside target, but faces near-term headwinds from technical weakness and margin compression. Key risks include competitive pressures in online gaming and execution challenges in maintaining growth momentum. Institutional buying activity, including BlackRock's $448M investment in August 2026, provides confidence in the long-term thesis despite current price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
